<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-5223-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TABIDEX 1 MG F. C. TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANASTROZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        105.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tabidex contains a substance called Anastrozole. This belongs to a<br />group of medicines called Aromatase Inhibitors. It is used to treat<br />breast cancer in women who have gone through the menopause.<br />Tabidex works by cutting down the amount of the hormone called<br />Estrogen that your body makes. It does this by blocking a natural<br />substance (an enzyme) in your body called &lsquo;Aromatase&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Tabidex<br />&bull; If you are allergic to Anastrozole or any of the other ingredients<br />of this medicine (listed in section 6)<br />&bull; If you are pregnant or breastfeeding (see the section called<br />&lsquo;Pregnancy and Breastfeeding&rsquo;).<br />Do not take Tabidex if any of the above apply to you. If you are not<br />sure, talk to your doctor or pharmacist before taking Tabidex.<br />Warnings and Precautions<br />Talk to your doctor, pharmacist or nurse before taking Tabidex if<br />you<br />&bull; still have menstrual periods and have not yet gone through the<br />menopause. Have osteoporosis or have had any condition that<br />affects the strength of your bones. Anastrozole lowers the levels<br />of female hormones and this may lead to a loss of the mineral<br />content of bones, which might decrease their strength. You may<br />have to have bone density tests during treatment. Your doctor can<br />give you medicine to prevent or treat the bone loss<br />&bull; are taking a medicine that contains Tamoxifen or medicines that<br />contain Estrogen (see the section called &lsquo;Other medicines and<br />Tabidex&rsquo;)<br />&bull; have ever had a condition that affects the strength of your bones<br />(osteoporosis) or<br />&bull; have problems with your liver or kidneys<br />If you are not sure if any of the above applies to you, talk to your<br />doctor or pharmacist before taking Tabidex.<br />If you go into the hospital, let the medical staff know you are taking<br />Tabidex.<br />Children and Adolescents<br />Tabidex should not be given to children and adolescents because it<br />is unlikely to be safe.<br />Other medicines and Tabidex<br />Tell your doctor or pharmacist if you are taking, have recently taken<br />or might take any other medicines, including medicines obtained<br />without a prescription. This includes medicines that you buy<br />without a prescription and herbal medicines. This is because<br />Anastrozole can affect the way some medicines work and some<br />medicines can have an effect on Anastrozole.<br />Do not take Tabidex if you are already taking any of the following<br />medicines:<br />&bull; Certain medicines used to treat breast cancer (selective oestrogen<br />receptor modulators), e.g., medicines that contain Tamoxifen.<br />This is because these medicines may stop Anastrozole from<br />working properly.<br />&bull; Medicines that contain oestrogen, such as hormone replacement<br />therapy (HRT).<br />If this applies to you, ask your doctor or pharmacist for advice.<br />Tell your doctor or pharmacist if you are taking the following:<br />&bull; LHRH analogues e.g. Gonadorelin, Buserelin, Goserelin,<br />Leuprorelin and Triptorelin. (medicines used to treat breast<br />cancer, certain gynaecological problems or infertility).<br />Tabidex with food and drink<br />There is no effect on absorption of Tabidex when taken with meal.<br />Pregnancy and Breastfeeding<br />Do not take Tabidex if you are pregnant or breastfeeding your<br />babies. Stop taking Tabidex if you are pregnant and talk to your<br />doctor.<br />Ask your doctor or pharmacist for advice before using any<br />medicine.<br />Driving and using machines<br />Tabidex is unlikely to adversely affect your ability to drive a car or<br />to operate machinery.<br />However, some patients may occasionally feel weak or sleepy. If<br />this happens to you, you should not drive or operate machinery and<br />ask your doctor or pharmacist for advice.<br />Tabidex contains lactose<br />Tabidex contains lactose which is a type of sugar. If your doctor has<br />told you that you have intolerance to some sugars, contact your<br />doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Tabidex exactly as your doctor has told you. You<br />should check with your doctor or pharmacist if you are not sure.<br />&bull; The usual adult dose is one tablet taken daily.<br />&bull; Swallow the tablet whole with a drink of water.<br />&bull; Try to take your tablet at the same time each day.<br />It does not matter if you take Tabidex before, with or after food.<br />Keep taking Tabidex for as long as your doctor or pharmacist tells<br />you to. It is a long term treatment and you may need to take it for<br />several years. Check with your doctor or pharmacist if you are not<br />sure. Do not stop taking your tablets even if you are feeling well,<br />unless your doctor tells you.<br />Children and Adolescents<br />Tabidex should not be given to children and adolescents because it<br />is unlikely to be safe.<br />If you take more Tabidex than you should<br />If you have taken more Tabidex than you were told to, or if<br />someone else has taken any Tabidex, contact accident and<br />emergency department of your nearest hospital. Take any leftover<br />tablets or empty box with you for easier identification.<br />If you forget to take Tabidex<br />Do not take double dose (two doses at the same time) to make up<br />for a forgotten dose; just resume your usual schedule.<br />If you stop taking Tabidex<br />Do not stop taking your tablets even if you are feeling well, unless<br />your doctor tells you.<br />If you have any further question on the use of the product, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Tabidex can cause side effects, although not<br />everybody gets them.<br />Stop taking Tabidex and seek urgent medical treatment, if you<br />experience any of the following serious but very rare side<br />effects:<br />&bull; An extremely severe skin reaction with ulcers or blisters on the<br />skin. This is known as &lsquo;Stevens-Johnson syndrome&rsquo;.<br />&bull; Allergic (hypersensitivity) reactions with swelling of the throat<br />that may cause difficulty in swallowing or breathing. This is<br />known as &lsquo;angioedema&rsquo;.<br />If one or some of these symptoms occur, you must tell your doctor<br />right away if you get one or more of these symptoms.<br />Very common (may affect more than 1 in 10 people)<br />&bull; Hot flushes<br />&bull; Feeling weak<br />&bull; Pain or stiffness in your joints<br />&bull; Inflammation of the joints (arthritis)<br />&bull; Skin rash<br />&bull; Feeling sick (nausea)<br />&bull; Headache<br />&bull; Bone loss (osteoporosis)<br />Common (may affect less than 1 in 10 people)<br />&bull; Vaginal dryness<br />&bull; Bleeding from vagina (usually in the first few weeks of<br />treatment-if the bleeding continues, talk to your doctor)<br />&bull; Thinning of your hair (hair loss)<br />&bull; Diarrhoea<br />&bull; Loss of appetite<br />&bull; Raised or high levels of a fatty substances known as cholesterol in<br />your blood. This would be seen in a blood test<br />&bull; Being sick (vomiting)<br />&bull; Feeling sleepy<br />&bull; Carpal tunnel syndrome (tingling, pain, coldness, weakness in<br />parts of the hand)<br />&bull; Tickling, tingling or numbness of skin, loss/lack of taste<br />&bull; Changes in blood tests that show how well your liver is working<br />&bull; Bone pain<br />&bull; Allergic (hypersensitivity) reactions including face, lips, or tongue<br />&bull; Muscle pain<br />Uncommon (may affect less than 1 in 100 people)<br />&bull; Trigger finger (a condition in which your finger or thumb catches<br />in a bent position)<br />&bull; Changes in special blood tests that show how your liver is<br />working (Gamma-GT and Bilirubin)<br />&bull; Inflammation of the liver (hepatitis)<br />&bull; Hives or nettle rash<br />&bull; Increased amounts of calcium in your blood. If you experience<br />nausea, vomiting and thirst, you should tell your doctor, or<br />pharmacist or nurse as you may need to have blood tests<br />Rare (may affect 1 to 10 people in 10,000)<br />&bull; Rare inflammation of your skin that may include red patches or<br />blisters<br />&bull; Inflammation of the small blood vessels causing red or purple<br />colouring of the skin. Very rarely symptoms of joint, stomach,<br />and kidney pain may occur; this is known as &lsquo;Henoch-Sch&ouml;nlein<br />purpura&rsquo;<br />If any of these happen to you, call an ambulance or see a doctor<br />straight away &ndash; you may need urgent medical treatment.<br />Effects on your bones<br />Anastrozole lowers the amount of the hormone called oestrogen that<br />is in your body. This may lower the mineral content of your bones.<br />Your bones may be less strong and may be more likely to fracture.<br />Your doctor will manage these according to treatment guidelines for<br />managing bone health in women who have gone through the<br />menopause. You should talk to your doctor about the risks and<br />treatment options.<br />If any of the side effects get serious, or if you notice any side effects<br />not listed in this leaflet, please tell your doctor or pharmacist.<br />Reporting of side effects<br />f you get any side effects, talk to your doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet. You<br />can also report the side effects directly to the National<br />Pharmacovigilance Centre (NPC) (see Section 6). By reporting side<br />effects, you can help provide more information on the safety of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.<br />Do not use this medicine after the expiry date which<br />is stated on the pack. The expiry date refers to the<br />last day of that month.<br />Do not use Tabidex if you notice any visible signs of<br />deterioration.<br />Medicines should not be disposed of via wastewater<br />or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required.<br />These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Anastrozole. Each film-coated tablet<br />contains 1mg of Anastrozole.<br />The other ingredient(s) are:<br />Tablet core: Lactose monohydrate, povidone K-30, sodium starch<br />glycolate (type A), magnesium stearate<br />Tablet coating: Titanium dioxide (E171), macrogol 300,<br />hypromellose E-5</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tabidex are white to off white in colour, round, biconvex,
film-coated tablets with ‘AHI’ debossing on one side and plain on
other side.
Tabidex is packed in blisters and is available in different pack sizes
(10 , 14 , 20 , 28, 30 , 50 , 56 , 60 , 84 , 90 , 98 , 100 or 300 tablets
per pack).
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom.<br />Manufactured for Accord Healthcare Limited by:<br />Intas Pharmaceuticals Limited, Ahmedabad, Gujarat state, India<br />For any information about this medicinal product, please contact us by:<br />E-mail: mena-pv@accord-healthcare.com<br />This leaflet was last approved in 11/2019, version number SA-02.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance Centre (NPC):<br />&bull; SFDA Call Centre: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 11/2019, version number SA-02.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي تابيدكس إلى مجموعة الأدوية المعروفة باسم مثبطات الأروماتاز، أي<br />أنه يتعارض مع بعض تأثيرات الأروماتاز وهو أحد الأنزيمات الموجودة في<br />الجسم التي تؤثر في مستويات بعض الهرمونات الجنسية في الإناث مثل<br />الإستروجين. يستخدم هذا الدواء في علاج سرطان الثدي في الإناث بعد سن<br />اليأس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول تابيدكس<br />&bull; إذا كنت تعاني من حساسية من الأناستروزول، أو أي مكون آخر من<br />مكونات هذا الدواء.<br />&bull; إذا لم تكون المريضة قد بلغت سن اليأس بالفعل.<br />&bull; إذا كانت المريضة حاملًا أو مرضعا.ً<br />&bull; إذا كنت تعاني من مرض الكبد بدرجة متوسطة أو شديدة.<br />&bull; إذا كنت تتناول أدوية أخرى تحتوي على الإستروجين (راجع أيضًا &quot;تناول<br />الأدوية الأخرى&quot; أدناه).<br />&bull; إذا كنت تتناول التاموكسيفين (راجع أيضًا &quot;تناول الأدوية الأخرى&quot; أدناه).<br />التحذيرات والاحتياطات<br />تحدث إلى الطبيب أو الصيدلي قبل تناول تابيدكس<br />&bull; إذا كنت تعاني من هشاشة العظام، أو أصبت من قبل بأي أمراض تؤثر في<br />صلابة العظام. يعمل الأناسترازول على خفض مستويات الهرمونات الجنسية<br />في الإناث مما قد يؤدي إلى فقدان محتويات العظام من المعادن ومن ثم قد يقلل<br />من صلابتها. قد تحتاج إلى إجراء الفحوصات الخاصة بقياس كثافة العظام أثناء<br />العلاج. قد يقوم الطبيب بإعطائك علاجًا لمنع أو علاج تآكل العظام.<br />&bull; إذا كانت المريضة غير متأكدة من بلوغها سن اليأس بعد. ينبغي على الطبيب<br />فحص مستويات الهرمونات.<br />&bull; إذا كنت قد أصبت من قبل بأي أمراض تؤثر في العظام (هشاشة العظام).<br />&bull; إذا كنت مصاب باضطرابات في الكبد أو الكلية.<br />الأطفال والمراهقون<br />لا ينبغي إعطاء تابيدكس للأطفال والمراهقين.</p><p>تابيدكس والأدوية الأخرى<br />أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول حاليًا، أو تناولت مؤخرًا، أو<br />قد تتناول لاحقًا أي أدوية أخرى، بما في ذلك الأدوية التي تصرف دون الحاجة<br />إلى وصفة طبية. يشمل ذلك الأدوية التي تصرف دون الحاجة إلى وصفة<br />طبية والأدوية العشبية. يرجع السبب في ذلك إلى قدرة الأناسترازول على<br />التأثير في آلية عمل بعض الأدوية الأخرى، كما قد تؤثر بعض الأدوية الأخرى<br />في آلية عمله أيضًا.<br />لا تتناول تابيدكس إذا كنت تتناول الأدوية التالية في الوقت الحالي:<br />&bull; بعض الأدوية المستخدمة في علاج سرطان الثدي (الموضحات الانتقائية<br />لمستقبلات الإستروجين) كالأدوية التي تحتوي على التاموكسيفين. يرجع<br />السبب في ذلك إلى أن هذه الأدوية قد تمنع عمل الأناسترازول بشكل مناسب.<br />&bull;الأدوية التي تحتوي على الإستروجين مثل العلاج التعويضي بالهرمونات.<br />اطلب نصيحة الطبيب المعالج أو الصيدلي إذا كان ما سبق ينطبق على حالتك<br />الصحية.<br />أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول الأدوية التالية:<br />&bull; نظائر الهرمون المطلق للهرمون الملوتن، مثل: جونادوريلين، وبوسيريلين،<br />وجوسيريلين، وليوبروليلين، وترايبتوريلين (تستخدم هذه الأدوية في علاج<br />سرطان الثدي، وبعض أمراض النساء، واضطرابات الخصوبة). لا توجد<br />دراسات تتعلق بتناول نظائر الهرمون المطلق للهرمون الملوتن و<br />الأناستروزول في ذات الوقت. لذا، ينبغي عدم تناول نظائر الهرمون المطلق<br />للهرمون الملوتن والأناستروزول في ذات الوقت.<br />يرجى إبلاغ الطبيب المعالج أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا أي<br />أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية.<br />تابيدكس مع الطعام والشراب<br />لا يؤثر الطعام في امتصاص تابيدكس.</p><p>الحمل ، الرضاعة الطبيعية والخصوبة<br />يجب عدم تناول تابيدكس إذا كانت المريضة حاملا او مرضعاً.<br />يجب التوقف عن تناول تابيدكس اذا اصبحت المريضة حاملا. يجب التحدث<br />الي الطبيب المعالج بهذا الشأن.<br />يجب طلب النصح من الطبيب أو الصيدلي قبل تناول هذا الدواء.<br />القيادة واستخدام الآلات<br />ليس لتابيدكس تأثيرات عكسية في القدرة على قيادة السيارة أو تشغيل الآلات.<br />قد يشعر بعض المرضى أحيانًا بالضعف أو الرغبة في النوم، وفي هذه الحالة<br />ينبغي الامتناع عن القيادة وتشغيل الآلات واستشارة الطبيب المعالج أو<br />الصيدلي.<br />معلومات مهمة بشأن بعض المكونات<br />يحتوي تابيدكس على اللاكتوز وهو أحد أنواع السكريات. يلزم إبلاغ الطبيب<br />المعالج قبل تناول هذا المستحضر الطبي إذا كان الطبيب قد أخبركِ مسبقاً بعدم<br />قدرتك على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول تابيدكس دائمًا كما يصفه الطبيب بالضبط. ينبغي مراجعة الطبيب أو<br />الصيدلي للتحقق من الوصفة الطبية.<br />&bull; تبلغ الجرعة المعتادة للبالغين قرصًا واحدًا يوميًّا.<br />&bull; ينبغي بلع القرص كاملًا مع شرب الماء.<br />&bull; حاول تناول القرص يوميًّا في نفس الوقت.<br />بإمكانك تناول تابيدكس قبل أو أثناء أو بعد تناول الطعام. تناول تابيدكس طوال<br />الفترة العلاجية التي يحددها لك الطبيب المعالج أو الصيدلي. يتم تناول هذا<br />الدواء لفترة طويلة، وقد تحتاج إلى استخدامه لعدة سنوات. تحدث إلى الطبيب<br />المعالج أو الصيدلي للتحقق من ذلك.<br />لا تتوقف عن استخدام الدواء حتى إذا شعرت بتحسن إلا بأمر الطبيب.<br />عند تناول كمية أكبر من اللازم من تابيدكس<br />اتصل بقسم الطوارئ في أقرب مستشفى إذا تناولت جرعة زائدة من تابيدكس،<br />أو إذا قام شخص آخر بتناول تابيدكس. اصطحب معك بقية الأقراص أو علبة<br />الدواء الفارغ لتسهيل التعرف على الدواء.<br />عند نسيان تناول الجرعة المقررة من تابيدكس<br />لا تتناول جرعة مضاعفة (جرعتين في وقت واحد) لتعويض الجرعة المنسية.<br />استأنف تناول الجرعات وفقًا للجدول العلاجي.<br />عند التوقف عن تناول تابيدكس<br />لا تتوقف عن استخدام الدواء حتى إذا شعرت بتحسن إلا بأمر الطبيب. إذا كان<br />لديك المزيد من الأسئلة حول استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع باقي الأدوية، قد يُسبب تابيدكس بعض الآثار الجانبية إلا أنها<br />قد لا تصيب الجميع.قد تكون بعض الآثار الجانبية خطيرة كما هو مُوضّح أدناه.<br />&bull; تفاعل جلدي شديد الذي يتمثل في القرح والبثور التي تظهر على الجلد.<br />تُعرف هذه الحالة باسم &quot;متلازمة ستيفنز-جونسون&quot;.<br />&bull; تفاعلات الحساسية المصحوبة بورم الحلق الذي يؤدي إلى صعوبة في البلع<br />أو التنفس. تُعرف هذه الحالة باسم &quot;الوذمة الوعائية&quot;.<br />إذا أُصبت بأحد هذه الأعراض أو بعضها، فيلزم إبلاغ الطبيب المعالج على<br />الفور.<br />الأكثر انتشارًا (تصيب أكثر من شخص واحد من بين ۱۰ أشخاص)<br />&bull; الاحمرار المصحوب بسخونة.<br />&bull; الشعور بالضعف.<br />&bull; ألم أو تصلب المفاصل.<br />&bull; التهاب المفاصل.<br />&bull; الطفح الجلدي (قد يشمل ذلك أحد أنواع الطفح الجلدي المعروف باسم<br />&quot;شرى&quot; أو &quot;طفح القراص&quot;).<br />&bull; الشعور بالإعياء (الغثيان).<br />&bull; الصداع.<br />&bull; فقدان العظام (هشاشة العظام).<br />شائعة (تصيب شخص واحد على الأكثر من بين ۱۰ أشخاص)<br />&bull; جفاف المهبل.<br />&bull; النزيف المهبلي (عادةً ما يحدث في الأسابيع القليلة الأولى من العلاج،<br />وينبغي إبلاغ الطبيب إذا استمر هذا النزيف).<br />&bull; تساقط الشعر.<br />&bull; الإسهال.<br />&bull; فقدان الشهية.<br />&bull; ارتفاع مستويات المواد الدهنية المعروفة باسم الكوليسترول في الدم.<br />يمكن التحقق من ذلك عن طريق تحليل الدم.<br />&bull; القيء.<br />&bull; الشعور بالنعاس.<br />&bull;متلازمة النفق الرسغي (التنميل، والألم، وبرودة، وضعف بعض المناطق<br />في اليد).<br />&bull; تغيرات في نتائج اختبارات الدم التي تبين وظيفة الكبد.<br />&bull; ألم العظام.<br />&bull; تفاعلات الحساسية التي تشمل الوجه والشفتين واللسان.<br />&bull; ألم العضلات.</p><p>غير شائعة (تصيب شخص واحد على الأكثر من بين ۱۰۰ شخص)<br />&bull; إصبع زنادية (وهو أحد الحالات التي يكون فيها الإصبع أو الإبهام متصلبًا<br />في وضعية الضغط على الزناد).<br />GT- &bull; تغيرات في نتائج اختبارات الدم التي تبين وظيفة الكبد (جاما<br />والبيليروبين).<br />&bull; التهاب الكبد الوبائي.<br />&bull; شرى أو طفح القراص.<br />&bull; ارتفاع مستوى الكالسيوم في الدم. ينبغي إبلاغ الطبيب المعالج أو الصيدلي<br />أو الممرضة عند الإصابة بالغثيان أو القيء أو الشعور بالعطش، فقد يكون من<br />الضروري إجراء فحوصات الدم.<br />نادرة (تصيب شخص واحد إلى ۱۰ أشخاص من بين ۱۰,۰۰۰ شخص)<br />&bull; التهابات الجلد النادرة التي قد تشمل البقع الحمراء أو البثور.<br />&bull; الطفح الجلدي الناجم عن الحساسية (قد ينجم ذلك عن تفاعلات الحساسية أو<br />التفاعلات التأقانية).<br />&bull; التهاب الشعيرات الدموية التي تسبب تلون الجلد باللون الأحمر أو البنفسجي.<br />أعراض نادرة جدًا تصيب المفاصل، والمعدة إضافة إلى ألم الكلية، تعرف هذه<br />الحالة باسم &quot;فرفرية هينوخ-شونلاين&quot;.<br />إذا أُصبت بأيٍّ من هذه الأعراض الجانبية، فاطلب الإسعاف أو توجه إلى<br />الطبيب على الفور لأنك قد تحتاج إلى رعاية طبية عاجلة.<br />تأثير الدواء في العظام<br />يعمل الأناستروزول على خفض كميات الهرمون المعروف باسم الإستروجين<br />في الجسم. قد يؤدي ذلك إلى خفض محتويات المعادن الموجودة في العظام.<br />قد تصبح العظام أقل صلابةً ومن ثم تسهل إصابتها بالكسور. سوف يقوم<br />الطبيب بعلاج ذلك وفقًا للتوجيهات العلاجية المتعلقة بسلامة العظام في النساء<br />اللاتي تخطين سن اليأس. ينبغي التحدث إلى الطبيب المعالج لمناقشة مخاطر<br />الدواء والخيارات العلاجية المتاحة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن مرأى و متناول أيدي الأطفال.<br />يجب عدم تخزين الدواء فوق ۳۰ درجة مئوية. يجب التخزين في العبوة<br />الأصلية.<br />لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة. يشير<br />تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.<br />لا تستخدم تابيدكس إذا لاحظت وجود أي علامات ظاهرة من التلف.<br />يجب عدم التخلص من الأدوية مع مياه الصرف الصحي أو النفايات المنزلية.<br />اطلب من الصيدلي معرفة كيفية التخلص من الأدوية التي لم تعد بحاجة إليها.<br />هذه الإجراءات ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعَالة هي أناستروزول. يحتوي كل قرص مغلف على ۱ ملغم من<br />أناستروزول.</p><p>المكونات الأخرى هي:<br />وجليكولات نشا ،K- أساس القرص: أحادي هيدرات اللاكتوز، وبوفيدون 30<br />الصوديوم (النوع أ)، وستيرات الماغنسيوم.<br />، ماكروجول ۳۰۰ ،(E الطبقة المغلفة للقرص: ثاني أكسيد التيتانيوم ( 171<br />.E-</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تابيدكس عبارة عن أقراص دائرية الشكل ذات لون أبيض مائل للاصفرار<br />،&quot;AHI&quot; ومحدبة من الجانبين. محفور على أحد جوانب القرص كلمة<br />وفارغة على الجانب الاخر.<br />يتوفر تابيدكس في شرائط وعبوات بأحجام مختلفة ( ۱۰ ، أو ۱٤ ، أو ۲۰ ، أو<br />، ۲۸ ، أو ۳۰ ، أو ٥۰ ، أو ٥٦ ، أو ٦۰ ، أو ۸٤ ، أو ۹۰ ، أو ۹۸ ، أو ۱۰۰<br />أو ۳۰۰ قرص لكل عبوة).<br />قد لا يتم طرح جميع الأحجام في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ححامل تصريح التسويق<br />شركة أكورد هيلثكير ليميتد<br />٤ إتش إف، ساج هاوس, ۳۱۹ بينر رود، نورث هارو، ميدلسيكس إتش أيه ۱<br />المملكة المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة في 06/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tabidex 1mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 1mg of Anastrozole.
Excipient(s):
Lactose monohydrate 95.250mg.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White to off white, round, biconvex, film-coated tablets with “AHI” debossing on one side and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of advanced breast cancer in postmenopausal women. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response to Tamoxifen.<br />Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.<br />Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant Tamoxifen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults including the elderly<br />One 1mg tablet to be taken orally once a day.<br />Children<br />Tabidex is not recommended for use in children due to insufficient data on safety and efficacy (see sections 4.4 and 5.1).<br />Renal impairment<br />No dose change is recommended in patients with mild or moderate renal impairment.<br />Hepatic impairment<br />No dose change is recommended in patients with mild hepatic disease.<br />For early disease, the recommended duration of treatment should be 5 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tabidex is contraindicated in:
• patients with known hypersensitivity to Anastrozole or to any of the excipients as referenced in section 6.1.
• premenopausal women.
• pregnant or lactating women.
• patients with moderate or severe hepatic disease.
Oestrogen containing therapies should not be coadministered with Anastrozole as they would negate its pharmacological action.
Concurrent Tamoxifen therapy (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Anastrozole should not be used in premenopausal women. The menopause should be defined biochemically (luteinizing hormone [LH], follicle stimulating hormone [FSH], and/or estradiol levels) in any patient where there is doubt about menopausal status. There are no data to support the use of Anastrozole with LHRH analogues.<br />Coadministration of Tamoxifen or oestrogen containing therapies with Anastrozole should be avoided as this may diminish its pharmacological action (see section 4.5 and 5.1).<br />Effect on bone mineral density<br />As Anastrozole lowers circulating oestrogen levels it may cause a reduction in bone mineral density with a possible consequent increased risk of fracture (see section 4.8).<br />Women with osteoporosis or at risk of osteoporosis, should have their bone mineral density formally assessed at the commencement of treatment and at regular intervals thereafter. Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored. The use of specific treatments, e.g., bisphosphonates, may stop further bone mineral loss caused by Anastrozole in postmenopausal women and could be considered (see section 4.8).</p><p>Hepatic impairment<br />Anastrozole has not been investigated in breast cancer patients with moderate or severe hepatic impairment. Exposure to Anastrozole can be increased in subjects with hepatic impairment (see section 5.2); administration of Anastrozole in patients with moderate and severe hepatic impairment should be performed with caution (see section 4.2). Treatment should be based on a benefit-risk evaluation for the individual patient.</p><p>Renal impairment<br />Anastrozole has not been investigated in breast cancer patients with severe renal impairment. Exposure to Anastrozole is not increased in subjects with severe renal impairment (GRF&lt;30ml/min, see section 5.2); in patients with severe renal impairment, administration of Anastrozole should be performed with caution (see section 4.2).<br />Paediatric population<br />Anastrozole is not recommended for use in children and adolescents as safety and efficacy have not been established in this group of patients (see section 5.1).<br />Anastrozole should not be used in boys with growth hormone deficiency in addition to growth hormone treatment. In the pivotal clinical trial, efficacy was not demonstrated and safety was not established (see section 5.1). Since Anastrozole reduces estradiol levels, Anastrozole must not be used in girls with&nbsp;growth hormone deficiency in addition to growth hormone treatment. Long-term safety data in children and adolescents are not available.<br />Hypersensitivity to lactose<br />This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anastrozole inhibits CYPs 1A2, 2C8/9 and 3A4 in vitro. Clinical studies with Antipyrine and Warfarin showed that Anastrozole at a 1mg dose did not significantly inhibit the metabolism of Antipyrine and R&ndash; and S-Warfarin indicating the coadministration of Anastrozole with other medicinal products is unlikely to result in clinically significant medicinal product interactions mediated by CYP enzymes.<br />The enzymes mediating metabolism of Anastrozole have not been identified. Cimetidine, a weak, unspecific inhibitor of CYP enzymes, did not affect the plasma concentrations of Anastrozole. The effect of potent CYP inhibitors is unknown.<br />A review of the clinical trial safety database did not reveal evidence of clinically significant interaction in patients treated with Anastrozole who also received other commonly prescribed medicinal products. There were no clinically significant interactions with bisphosphonates (see section 5.1).<br />Coadministration of Tamoxifen or oestrogen-containing therapies with Anastrozole should be avoided as this may diminish its pharmacological action (see section 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy Category (X).<br />There are no data from the use of Anastrozole in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Anastrozole is contraindicated during pregnancy (see section 4.3).<br />Breastfeeding<br />There are no data on the use of Anastrozole during lactation. Anastrozole is contraindicated during breastfeeding (see section 4.3).<br />Fertility<br />The effects of Anastrozole on fertility in humans have not been studied. Studies in animals have shown reproductive toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anastrozole has no or negligible influence on the ability to drive and use machines. However, asthenia and somnolence have been reported with the use of Anastrozole and caution should be observed when driving or operating machinery while such symptoms persist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following table presents adverse reactions from clinical trials, post-marketing studies or spontaneous reports. Unless specified, the frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9,366 postmenopausal women with&nbsp;operable breast cancer given adjuvant treatment for five years (the Anastrozole, Tamoxifen, Alone or in Combination [ATAC] study).<br />Adverse reactions listed below are classified according to frequency and System Organ Class (SOC). Frequency groupings are defined according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt;1/1,000), and very rare (&lt;1/10,000). The most frequently reported adverse reactions were headache, hot flushes, nausea, rash, arthralgia, joint stiffness, arthritis, and asthenia.<br />Table 1 Adverse reactions by System Organ Class and frequency</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction </strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p><p>(&ge;1/10)</p></td><td colspan="2" style="vertical-align:top"><p>Vascular</p></td><td style="vertical-align:top"><p>Hot flushes</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia/ Joint stiffness, arthritis, Osteoporosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system</p></td><td colspan="2" style="vertical-align:top"><p>Headache,</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal</p></td><td colspan="2" style="vertical-align:top"><p>Nausea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td><td colspan="2" style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>(&ge;1/100 to &lt;1/10)</p></td><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td><td style="vertical-align:top"><p>Hair thinning (Alopecia), Allergic reactions</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal</p></td><td colspan="2" style="vertical-align:top"><p>Vomiting, Diarrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system</p></td><td colspan="2" style="vertical-align:top"><p>Somnolence, Carpal tunnel syndrome*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td colspan="2" style="vertical-align:top"><p>Increases in alkaline phosphatase, Alanine Aminotransferase and Aspartate Aminotransferase</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Reproductive system and breast</p></td><td colspan="2" style="vertical-align:top"><p>Vaginal bleeding***, Vaginal dryness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition</p></td><td colspan="2" style="vertical-align:top"><p>Anorexia, Hypercholesterolemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal connective tissue and bone</p></td><td colspan="2" style="vertical-align:top"><p>Bone pain, Muscle pain.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>(&ge;1/1,000 to &lt;1/100)</p></td><td colspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Increases in Gamma-GT and Bilirubin, hepatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td><td colspan="2" style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition</p></td><td colspan="2" style="vertical-align:top"><p>Hypercalcaemia (with or without an increase in parathyroid hormone)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal connective tissue and bone</p></td><td colspan="2" style="vertical-align:top"><p>Trigger finger</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p><p>(&lt;1/10,000)</p></td><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td><td style="vertical-align:top"><p>Erythema multiforme,</p><p>Anaphylactoid reaction,</p><p>Cutaneous vasculitis (including some reports of Henoch-Sch&ouml;nlein purpura)**</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td><td style="vertical-align:top"><p>Steven-Johnson syndrome, Anigoedema</p></td></tr></tbody></table><p>* Events of Carpal Tunnel Syndrome have been reported in patients receiving Anastrozole treatment in clinical trials in greater numbers than those receiving treatment with Tamoxifen. However, the majority of these events occurred in patients with identifiable risk factors for the development of the condition.<br />** Since cutaneous vasculitis and Henoch-Sch&ouml;nlein purpura was not observed in ATAC, the frequency category for these events can be considered as &#39;Rare&#39; (&ge; 0.01% and &lt; 0.1%) based on the worst value of the point estimate.<br />*** Vaginal bleeding has been reported commonly, mainly in patients with advanced breast cancer during the first few weeks after changing from existing hormonal therapy to treatment with Anastrozole. If bleeding persists, further evaluation should be considered.<br />The table below presents the frequency of pre-specified adverse events in the ATAC study after a median follow up of 68 months, irrespective of causality, reported in patients receiving trial therapy and up to 14 days after cessation of trial therapy.</p><p>Table 2 ATAC study pre-specified adverse events</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse events </strong></p></td><td style="vertical-align:top"><p><strong>Anastrozole </strong></p><p><strong>(N=3,092) </strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen </strong></p><p><strong>(N=3,094) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Hot flushes</p></td><td style="vertical-align:top"><p>1,104 (35.7%)</p></td><td style="vertical-align:top"><p>1,264 (40.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Joint pain/stiffness</p></td><td style="vertical-align:top"><p>1,100 (35.6%)</p></td><td style="vertical-align:top"><p>911 (29.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Mood disturbances</p></td><td style="vertical-align:top"><p>597 (19.3%)</p></td><td style="vertical-align:top"><p>554 (17.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue/asthenia</p></td><td style="vertical-align:top"><p>575 (18.6%)</p></td><td style="vertical-align:top"><p>544 (17.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea and vomiting</p></td><td style="vertical-align:top"><p>393 (12.7%)</p></td><td style="vertical-align:top"><p>384 (12.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Fractures</p></td><td style="vertical-align:top"><p>315 (10.2%)</p></td><td style="vertical-align:top"><p>209 (6.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Fractures of the spine, hip, or wrist/Colles</p></td><td style="vertical-align:top"><p>133 (4.3%)</p></td><td style="vertical-align:top"><p>91 (2.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Wrist/Colles fractures</p></td><td style="vertical-align:top"><p>67 (2.2%)</p></td><td style="vertical-align:top"><p>50 (1.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Spine fractures</p></td><td style="vertical-align:top"><p>43 (1.4%)</p></td><td style="vertical-align:top"><p>22 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Hip fractures</p></td><td style="vertical-align:top"><p>28 (0.9%)</p></td><td style="vertical-align:top"><p>26 (0.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Cataracts</p></td><td style="vertical-align:top"><p>182 (5.9%)</p></td><td style="vertical-align:top"><p>213 (6.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal bleeding</p></td><td style="vertical-align:top"><p>167 (5.4%)</p></td><td style="vertical-align:top"><p>317 (10.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Ischaemic cardiovascular disease</p></td><td style="vertical-align:top"><p>127 (4.1%)</p></td><td style="vertical-align:top"><p>104 (3.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>71 (2.3%)</p></td><td style="vertical-align:top"><p>51 (1.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarct</p></td><td style="vertical-align:top"><p>37 (1.2%)</p></td><td style="vertical-align:top"><p>34 (1.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Coronary artery disorder</p></td><td style="vertical-align:top"><p>25 (0.8%)</p></td><td style="vertical-align:top"><p>23 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial ischaemia</p></td><td style="vertical-align:top"><p>22 (0.7%)</p></td><td style="vertical-align:top"><p>14 (0.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal discharge</p></td><td style="vertical-align:top"><p>109 (3.5%)</p></td><td style="vertical-align:top"><p>408 (13.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Any venous thromboembolic event</p></td><td style="vertical-align:top"><p>87 (2.8%)</p></td><td style="vertical-align:top"><p>140 (4.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Deep venous thromboembolic events including PE (pulmonary embolism)</p></td><td style="vertical-align:top"><p>48 (1.6%)</p></td><td style="vertical-align:top"><p>74 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Ischaemic cerebrovascular events</p></td><td style="vertical-align:top"><p>62 (2.0%)</p></td><td style="vertical-align:top"><p>88 (2.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial cancer</p></td><td style="vertical-align:top"><p>4 (0.2%)</p></td><td style="vertical-align:top"><p>13 (0.6%)</p></td></tr></tbody></table><p>&nbsp;</p><p>Fracture rates of 22 per 1,000 patient-years and 15 per 1,000 patient-years were observed for the Anastrozole and Tamoxifen groups, respectively, after a median follow up of 68 months. The observed fracture rate for Anastrozole is similar to the range reported in age matched postmenopausal populations. The incidence of osteoporosis was 10.5% in patients treated with Anastrozole and 7.3% in patients treated with Tamoxifen.<br />It has not been determined whether the rates of fracture and osteoporosis seen in ATAC in patients on<br />Anastrozole treatment reflect a protective effect of Tamoxifen, a specific effect of Anastrozole, or both.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited clinical experience of accidental overdosage. In animal studies, Anastrozole demonstrated low acute toxicity. Clinical trials have been conducted with various dosages of Anastrozole, up to 60mg in a single dose given to healthy male volunteers and up to 10mg daily given to postmenopausal women with advanced breast cancer; these dosages were well tolerated. A single dose of Anastrozole that results in life threatening symptoms has not been established. There is no specific antidote to overdosage and treatment must be symptomatic.<br />In the management of an overdose, consideration should be given to the possibility that multiple agents may have been taken. Vomiting may be induced if the patient is alert. Dialysis may be helpful because Anastrozole is not highly protein bound. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<br />Enzyme inhibitors, ATC code: L02BG03<br />Mechanism of action and Pharmacodynamic effects<br />Anastrozole is a potent and highly selective non-steroidal Aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the Aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Anastrozole at a daily dose of 1mg produced estradiol suppression of greater than 80% using a highly sensitive assay.<br />Anastrozole does not possess any progestogenic, androgenic, or estrogenic activity.</p><p>Daily doses of Anastrozole up to 10mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard Adrenocorticotrophic hormone (ACTH) challenge testing. Corticoid supplements are therefore not needed.<br />Clinical efficacy and safety<br />Advanced breast cancer<br />First-line therapy in postmenopausal women with advanced breast cancer<br />Two double-blind, controlled clinical studies of similar design (Study 1033IL/0030 and Study 1033IL/0027) were conducted to assess the efficacy of Anastrozole compared with Tamoxifen as first-line therapy for hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer in postmenopausal women. A total of 1,021 patients were randomized to receive 1mg of Anastrozole once daily or 20mg of Tamoxifen once daily. The primary endpoints for both trials were time to tumour progression, objective tumour response rate, and safety.<br />For the primary endpoints, Study 1033IL/0030 showed that Anastrozole had a statistically significant advantage over Tamoxifen for time to tumour progression (Hazard ratio (HR) 1.42, 95% Confidence Interval (CI) [1.11, 1.82], Median time to progression 11.1 and 5.6 months for Anastrozole and Tamoxifen respectively, p=0.006); objective tumour response rates were similar for Anastrozole and Tamoxifen. Study 1033IL/0027 showed that Anastrozole and Tamoxifen had similar objective tumour response rates and time to tumour progression. Results from the secondary endpoints were supportive of the results of the primary efficacy endpoints. There were too few deaths occurring across treatment groups of both trials to draw conclusions on overall survival differences.</p><p>Second-line therapy in postmenopausal women with advanced breast cancer<br />Anastrozole was studied in two controlled clinical trials (Study 0004 and Study 0005) in postmenopausal women with advanced breast cancer who had disease progression following Tamoxifen therapy for either advanced or early breast cancer. A total of 764 patients were randomized to receive either a single daily dose of 1mg or 10mg of Anastrozole or Megestrol Acetate 40mg four times a day. Time to progression and objective response rates were the primary efficacy variables. The rate of prolonged (more than 24 weeks) stable disease, the rate of progression, and survival were also calculated. In both studies there were no significant differences between treatment arms with respect to any of the efficacy parameters.</p><p>Adjuvant treatment of early invasive breast cancer for hormone receptor-positive patients<br />In a large phase III study conducted in 9,366 postmenopausal women with operable breast cancer treated for 5 years (see below), Anastrozole was shown to be statistically superior to Tamoxifen in disease-free survival. A greater magnitude of benefit was observed for disease free survival in favour of Anastrozole versus Tamoxifen for the prospectively defined hormone receptor-positive population.<br />ATAC study have not been followed up for sufficient time after 5 years of treatment, to enable a comparison of long-term post treatment effects of Anastrozole relative to Tamoxifen.</p><p>Table 3 ATAC endpoint summary: 5-year treatment completion analysis</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Efficacy endpoints </strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Number of events (frequency) </strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Intention-to-treat population </strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Hormone-receptor-positive tumor status </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Anastrozole </strong></p><p><strong>(N=3125) </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Tamoxifen </strong></p><p><strong>(N=3116) </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Anastrozole </strong></p><p><strong>(N=2618) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Tamoxifen </strong></p><p><strong>(N=2598) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease-free survival</strong><strong>a </strong></p></td><td colspan="3" style="vertical-align:top"><p>575(18.4)</p></td><td colspan="2" style="vertical-align:top"><p>651(20.9)</p></td><td colspan="3" style="vertical-align:top"><p>424(16.2)</p></td><td style="vertical-align:top"><p>497(19.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="4" style="vertical-align:top"><p>0.87</p></td><td colspan="3" style="vertical-align:top"><p>0.83</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="4" style="vertical-align:top"><p>0.78 to 0.97</p></td><td colspan="3" style="vertical-align:top"><p>0.73 to 0.94</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>p-value</p></td><td colspan="4" style="vertical-align:top"><p>0.0127</p></td><td colspan="3" style="vertical-align:top"><p>0.0049</p></td></tr><tr><td style="vertical-align:top"><p><strong>Distant disease-free survival</strong><strong>b </strong></p></td><td colspan="3" style="vertical-align:top"><p>500(16.0)</p></td><td colspan="2" style="vertical-align:top"><p>530(17.0)</p></td><td colspan="3" style="vertical-align:top"><p>370(14.1)</p></td><td style="vertical-align:top"><p>394(15.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="4" style="vertical-align:top"><p>0.94</p></td><td colspan="3" style="vertical-align:top"><p>0.93</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="4" style="vertical-align:top"><p>0.83 to 1.06</p></td><td colspan="3" style="vertical-align:top"><p>0.80 to 1.07</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>p-value</p></td><td colspan="4" style="vertical-align:top"><p>0.2850</p></td><td colspan="3" style="vertical-align:top"><p>0.2838</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to recurrencec </strong></p></td><td colspan="3" style="vertical-align:top"><p>402(12.9)</p></td><td colspan="2" style="vertical-align:top"><p>498(16.0)</p></td><td colspan="3" style="vertical-align:top"><p>282(10.8)</p></td><td style="vertical-align:top"><p>370(14.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="4" style="vertical-align:top"><p>0.79</p></td><td colspan="3" style="vertical-align:top"><p>0.74</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="4" style="vertical-align:top"><p>0.70 to 0.90</p></td><td colspan="3" style="vertical-align:top"><p>0.64 to 0.87</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>p-value</p></td><td colspan="4" style="vertical-align:top"><p>0.0005</p></td><td colspan="3" style="vertical-align:top"><p>0.0002</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to distant recurrenced </strong></p></td><td colspan="3" style="vertical-align:top"><p>324(10.4)</p></td><td colspan="2" style="vertical-align:top"><p>375(12.0)</p></td><td colspan="3" style="vertical-align:top"><p>226(8.6)</p></td><td style="vertical-align:top"><p>265(10.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="4" style="vertical-align:top"><p>0.86</p></td><td colspan="3" style="vertical-align:top"><p>0.84</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="4" style="vertical-align:top"><p>0.74 to 0.99</p></td><td colspan="3" style="vertical-align:top"><p>0.70 to 1.00</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>p-value</p></td><td colspan="4" style="vertical-align:top"><p>0.0427</p></td><td colspan="3" style="vertical-align:top"><p>0.0559</p></td></tr><tr><td style="vertical-align:top"><p><strong>Contralateral breast primary </strong></p></td><td colspan="3" style="vertical-align:top"><p>35(1.1)</p></td><td colspan="2" style="vertical-align:top"><p>59(1.9)</p></td><td colspan="3" style="vertical-align:top"><p>26(1.0)</p></td><td style="vertical-align:top"><p>54(2.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Odds ratio</p></td><td colspan="4" style="vertical-align:top"><p>0.59</p></td><td colspan="3" style="vertical-align:top"><p>0.47</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="4" style="vertical-align:top"><p>0.39 to 0.89</p></td><td colspan="3" style="vertical-align:top"><p>0.30 to 0.76</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>p-value</p></td><td colspan="4" style="vertical-align:top"><p>0.0131</p></td><td colspan="3" style="vertical-align:top"><p>0.0018</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival e </strong></p></td><td colspan="3" style="vertical-align:top"><p>411(13.2)</p></td><td colspan="2" style="vertical-align:top"><p>420(13.5)</p></td><td colspan="3" style="vertical-align:top"><p>296(11.3)</p></td><td style="vertical-align:top"><p>301(11.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="4" style="vertical-align:top"><p>0.97</p></td><td colspan="3" style="vertical-align:top"><p>0.97</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="4" style="vertical-align:top"><p>0.85 to 1.12</p></td><td colspan="3" style="vertical-align:top"><p>0.83 to 1.14</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>p-value</p></td><td colspan="4" style="vertical-align:top"><p>0.7142</p></td><td colspan="3" style="vertical-align:top"><p>0.7339</p></td></tr></tbody></table><p>a. Disease-free survival includes all recurrence events and is defined as the first occurrence of loco-regional recurrence, contralateral new breast cancer, distant recurrence or death (for any reason).<br />b. Distant disease-free survival is defined as the first occurrence of distant recurrence or death (for any reason).<br />c. Time to recurrence is defined as the first occurrence of loco-regional recurrence, contralateral new breast cancer, distant recurrence or death due to breast cancer.<br />d. Time to distant recurrence is defined as the first occurrence of distant recurrence or death due to breast cancer.<br />e. Number (%) of patients who had died.<br />The combination of Anastrozole and Tamoxifen did not demonstrate any efficacy benefits in comparison with Tamoxifen in all patients as well as in the hormone receptor-positive population. This treatment arm was discontinued from the study.&nbsp;</p><p>With an updated follow up at a median of 10 years, long term comparison of the treatment effects of Anastrozole relative to Tamoxifen were shown to be consistent with previous analyses.<br />Adjuvant treatment of early invasive breast cancer for hormone receptor-positive patients being treated with adjuvant Tamoxifen<br />In a phase III trial (Austrian Breast and Colorectal Cancer Study Group [ABCSG] 8) conducted in 2,579 postmenopausal women with hormone receptor-positive early breast cancer who had received surgery with or without radiotherapy and no chemotherapy (see below), switching to Anastrozole after 2 years adjuvant treatment with Tamoxifen was statistically superior in disease-free survival when compared to remaining on Tamoxifen, after a median follow up of 24 months.</p><p>Table 4 ABCSG 8 trial endpoint and results summary</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Efficacy endpoints </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Number of events (frequency) </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Anastrozole </strong></p><p><strong>(N=1,297) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Tamoxifen </strong></p><p><strong>(N=1,282) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease-free survival </strong></p></td><td colspan="2" style="vertical-align:top"><p>65(5.0)</p></td><td style="vertical-align:top"><p>93(7.3)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.67</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="2" style="vertical-align:top"><p>0.49 to 0.92</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.014</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to any recurrence </strong></p></td><td colspan="2" style="vertical-align:top"><p>36(2.8)</p></td><td style="vertical-align:top"><p>66(5.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.53</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="2" style="vertical-align:top"><p>0.35 to 0.79</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to distant recurrence </strong></p></td><td colspan="2" style="vertical-align:top"><p>22 (1.7)</p></td><td style="vertical-align:top"><p>41(3.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.52</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="2" style="vertical-align:top"><p>0.31 to 0.88</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.015</p></td></tr><tr><td style="vertical-align:top"><p><strong>New contralateral breast cancer </strong></p></td><td colspan="2" style="vertical-align:top"><p>7(0.5)</p></td><td style="vertical-align:top"><p>15(1.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Odds ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.46</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="2" style="vertical-align:top"><p>0.19 to 1.13</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.090</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival </strong></p></td><td colspan="2" style="vertical-align:top"><p>43(3.3)</p></td><td style="vertical-align:top"><p>45(3.5)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.96</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>2-sided 95% CI</p></td><td colspan="2" style="vertical-align:top"><p>0.63 to 1.46</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.840</p></td></tr></tbody></table><p>Two further similar trials (GABG/ARNO 95 and ITA), in one of which patients had received surgery and chemotherapy, as well as a combined analysis of ABCSG 8 and GABG/ARNO 95, supported these results.<br />The Anastrozole safety profile in these 3 studies was consistent with the known safety profile established in postmenopausal women with hormone receptor-positive early breast cancer.</p><p>Bone mineral density (BMD)<br />In the phase III/IV study (Study of Anastrozole with the Bisphosphonate Risedronate [SABRE]), 234 postmenopausal women with hormone receptor-positive early breast cancer scheduled for treatment with Anastrozole 1mg/day were stratified to low, moderate and high-risk groups according to their existing risk of fragility fracture. The primary efficacy parameter was the analysis of lumbar spine bone mass density using DEXA scanning. All patients received treatment with vitamin D and calcium. Patients in the low-risk group received Anastrozole alone (N=42), those in the moderate group were randomized to Anastrozole plus Risedronate 35mg once a week (N=77) or Anastrozole plus placebo (N=77) and those in the high-risk group received Anastrozole plus Risedronate 35mg once a week (N=38). The primary endpoint was change from baseline in lumbar spine bone mass density at 12 months.<br />The 12-month main analysis has shown that patients already at moderate to high risk of fragility fracture showed no decrease in their bone mass density (assessed by lumbar spine bone mineral density using DEXA scanning) when managed by using Anastrozole 1mg/day in combination with Risedronate 35mg once a week. In addition, a decrease in BMD which was not statistically significant was seen in the low-risk group treated with Anastrozole 1mg/day alone. These findings were mirrored in the secondary efficacy variable of change from baseline in total hip BMD at 12 months.<br />This study provides evidence that the use of bisphosphonates could be considered in the management of possible bone mineral loss in postmenopausal women with early breast cancer scheduled to be treated with Anastrozole.<br />Paediatric population<br />Anastrozole is not indicated for use in children and adolescents. Efficacy has not been established in the paediatric populations studied (see below). The number of children treated was too limited to draw any reliable conclusions on safety. No data on the potential long-term effects of Anastrozole treatment in children and adolescents are available (see also section 5.3).<br />The European Medicines Agency has waived the obligation to submit the results of studies with Anastrozole in one or several subsets of the paediatric population in short stature due to growth hormone deficiency (GHD), testotoxicosis, gynaecomastia, and McCune-Albright syndrome (see section 4.2).</p><p>Short stature due to Growth Hormone Deficiency<br />A randomized, double-blind, multicenter study evaluated 52 pubertal boys (aged 11 to 16 years inclusive) with GHD treated for 12 to 36 months with Anastrozole 1mg/day or placebo in combination with growth hormone. Only 14 subjects on Anastrozole completed 36 months.<br />No statistically significant difference from placebo was observed for the growth related parameters of predicted adult height, height, height SDS (standard deviation score), and height velocity. Final height data were not available. While the number of children treated was too limited to draw any reliable conclusions on safety, there was an increased fracture rate and a trend towards reduced bone mineral density in the Anastrozole arm compared to placebo.<br />Testotoxicosis<br />An open-label, non-comparative, multicenter study evaluated 14 male patients (aged 2 to 9 years) with familial male-limited precocious puberty, also known as testotoxicosis, treated with combination of Anastrozole and Bicalutamide. The primary objective was to assess the efficacy and safety of this combination regimen over 12 months. Thirteen out of the 14 patients enrolled completed 12 months of combination treatment (one patient was lost to follow-up). There was no significant difference in growth rate after 12 months of treatment, relative to the growth rate during the 6 months prior to entering the study.<br />Gynaecomastia studies<br />Trial 0006 was a randomized, double-blind, multicenter study of 82 pubertal boys (aged 11-18 years inclusive) with gynaecomastia of greater than 12 months duration treated with Anastrozole 1mg/day or&nbsp;placebo daily for up to 6 months. No significant difference in the number of patients who had a 50% or greater reduction in total breast volume after 6 months of treatment was observed between the Anastrozole 1mg treated group and the placebo group.<br />Trial 0001 was an open-label, multiple-dose pharmacokinetic study of Anastrozole 1mg/day in 36 pubertal boys with gynaecomastia of less than 12 months duration. The secondary objectives were to evaluate the proportion of patients with reductions from baseline in the calculated volume of gynaecomastia of both breasts combined of at least 50% between day 1 and after 6 months of study treatment, and patient tolerability and safety. A decrease in 50% or more of total breast volume was seen in 56% (20/36) of the boys after 6 months.<br />McCune-Albright Syndrome study<br />Trial 0046 was an international , multicenter, open-label exploratory trial of Anastrozole in 28 girls (aged 2 to &le; 10 years) with McCune-Albright Syndrome (MAS). The primary objective was to evaluate the safety and efficacy of Anastrozole 1mg/day in patients with MAS. The efficacy of study treatment was based on the proportion of patients fulfilling defined criteria relating to vaginal bleeding, bone age, and growth velocity. No statistically significant change in the frequency of vaginal bleeding days on treatment was observed. There were no clinically significant changes in Tanner staging, mean ovarian volume, or mean uterine volume. No statistically significant change in the rate of increase in bone age on treatment compared to the rate during baseline was observed. Growth rate (in cm/year) was significantly reduced (p&lt;0.05) from pre-treatment through month 0 to month 12, and from pre-treatment to the second 6 months (month 7 to month 12).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Absorption of Anastrozole is rapid and maximum plasma concentrations typically occur within two hours of dosing (under fasted conditions). Food slightly decreases the rate but not the extent of absorption. The small change in the rate of absorption is not expected to result in a clinically significant effect on steady-state plasma concentrations during once daily dosing of Anastrozole. Approximately 90 to 95% of plasma Anastrozole steady-state concentrations are attained after 7 daily doses, and accumulation is 3- to 4-fold. There is no evidence of time or dose-dependency of Anastrozole pharmacokinetic parameters.<br />Anastrozole pharmacokinetics are independent of age in postmenopausal women.</p><p>Distribution<br />Anastrozole is only 40% bound to plasma proteins.</p><p>Elimination<br />Anastrozole is eliminated slowly with a plasma elimination half-life of 40 to 50 hours. Anastrozole is extensively metabolized by postmenopausal women with less than 10% of the dose excreted in the urine unchanged within 72 hours of dosing. Metabolism of Anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. The metabolites are excreted primarily via the urine. Triazole, the major metabolite in plasma, does not inhibit Aromatase.<br />Renal or hepatic impairment<br />The apparent clearance (CL/F) of Anastrozole, following oral administration, was approximately 30% lower in volunteers with stable hepatic cirrhosis than in matched controls (Study 1033IL/0014). However, plasma Anastrozole concentrations in the volunteers with hepatic cirrhosis were within the range of concentrations seen in normal subjects in other trials. Plasma Anastrozole concentrations observed during long-term efficacy trials in patients with hepatic impairment were within the range of plasma Anastrozole concentrations seen in patients without hepatic impairment.</p><p>The apparent clearance (CL/F) of Anastrozole, following oral administration, was not altered in volunteers with severe renal impairment (GFR &lt;30ml/min) in Study 1033IL/0018, consistent with the fact that Anastrozole is eliminated primarily by metabolism. Plasma Anastrozole concentrations observed during long- term efficacy trials in patients with renal impairment were within the range of plasma Anastrozole concentrations seen in patients without renal impairment. In patients with severe renal impairment, administration of Anastrozole should be performed with caution (see section 4.2 and 4.4).<br />Paediatric population<br />In boys with pubertal gynaecomastia (10-17 years), Anastrozole was rapidly absorbed, was widely distributed, and was eliminated slowly with a half-life of approximately 2 days. Clearance of Anastrozole was lower in girls (3-10 years) than in the older boys and exposure higher. Anastrozole in girls was widely distributed and slowly eliminated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction for the indicated population.<br />Acute toxicity<br />In animal studies toxicity was only seen at high doses. In acute toxicity studies in rodents, the median lethal dose of Anastrozole was greater than 100mg/kg/day by the oral route and greater than 50 mg/kg/day by the intraperitoneal route. In an oral acute toxicity study in the dog, the median lethal dose was greater than 45mg/kg/day.<br />Chronic toxicity<br />In animal studies adverse effects were only seen at high doses. Multiple dose toxicity studies utilized rats and dogs. No no-effect levels were established for Anastrozole in the toxicity studies, but those effects that were observed at the low doses (1mg/kg/day) and mid doses (dog 3mg/kg/day; rat 5mg/kg/day) were related to either the pharmacological or enzyme inducing properties of Anastrozole and were unaccompanied by significant toxic or degenerative changes.</p><p>Mutagenicity<br />Genetic toxicology studies with Anastrozole show that it is not a mutagen or a clastogen.<br />Reproductive toxicology<br />In a fertility study weanling male rats were dosed orally with 50 or 400mg/l Anastrozole via their drinking water for 10 weeks. Measured mean plasma concentrations were 44.4 (&plusmn;14.7) ng/ml and 165 (&plusmn;90) ng/ml respectively. Mating indices were adversely affected in both dose groups, whilst a reduction in fertility was evident only at the 400mg/l dose level. The reduction was transient as all mating and fertility parameters were similar to control group values following a 9 week treatment-free recovery period.<br />Oral administration of Anastrozole to female rats produced a high incidence of infertility at 1mg/kg/day and increased pre-implantation loss at 0.02mg/kg/day. These effects occurred at clinically relevant doses. An effect in man cannot be excluded. These effects were related to the pharmacology of the compound and were completely reversed after a 5-week compound withdrawal period.<br />Oral administration of Anastrozole to pregnant rats and rabbits caused no teratogenic effects at doses up to 1.0 and 0.2mg/kg/day respectively. Those effects that were seen (placental enlargement in rats and pregnancy failure in rabbits) were related to the pharmacology of the compound.</p><p>The survival of litters born to rats given Anastrozole at 0.02mg/kg/day and above (from Day 17 of pregnancy to Day 22 post-partum) was compromised. These effects were related to the pharmacological<br />effects of the compound on parturition. There were no adverse effects on behaviour or reproductive performance of the first generation offspring attributable to maternal treatment with Anastrozole.<br />Carcinogenicity<br />A two-year rat oncogenicity study resulted in an increase in incidence of hepatic neoplasms and uterine stromal polyps in females and thyroid adenomas in males at the high dose (25mg/kg/day) only. These changes occurred at a dose which represents 100-fold greater exposure than occurs at human therapeutic doses, and are considered not to be clinically relevant to the treatment of patients with Anastrozole.<br />A two-year mouse oncogenicity study resulted in the induction of benign ovarian tumours and a disturbance in the incidence of lymphoreticular neoplasms (fewer histiocytic sarcomas in females and more deaths as a result of lymphomas). These changes are considered to be mouse-specific effects of Aromatase inhibition and not clinically relevant to the treatment of patients with Anastrozole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet Core<br />Lactose Monohydrate<br />Povidone K-30<br />Sodium Starch Glycolate (Type A)<br />Magnesium Stearate<br />Tablet coating<br />Hypromellose E-5<br />Macrogol 300<br />Titanium Dioxide E171</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tabidex are white to off white in colour, round, biconvex, film-coated tablets with &lsquo;AHI&rsquo; debossing on one side and plain on other side.<br />Tabidex is packed in blisters and is available in different pack sizes (10 , 14 , 20 , 28, 30 , 50 , 56 , 60 , 84 , 90 , 98 , 100 or 300 tablets per pack).</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319, Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom
Tel: +44 208 863 1427
Fax: +44 208 863 1426
E-mail: mena-info@accord-healthcare.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2015 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>